Clinical Trials Browser

Not yet recruiting × toripalimab × Thoracic × Clear all

NCT07376499 2026-01-29

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

Phase 2 Not yet recruiting

Small Cell Lung Carcinoma

NCT07358689 2026-01-22

Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer

Phase 2 Not yet recruiting

NSCLC

NCT07308379 2025-12-29

Real-World Study of Toripalimab in Extensive-Stage Small Cell Lung Cancer

Not yet recruiting

SCLC, Extensive Stage

NCT07286942 2025-12-16

Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07097948 2025-08-01

Adjuvant

Phase 2 Not yet recruiting

Recurrence, Small Cell Lung Carcinoma

NCT06732258 2024-12-27

Low-dose Radiotherapy Combined with Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC

Phase 1 Not yet recruiting

Small Cell Lung Carcinoma

NCT06709274 2024-11-29

MOTION-NSCLC

Phase NA Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06648200 2024-10-18

Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer

Phase 2 Not yet recruiting

Recurrence, Small Cell Lung Carcinoma

NCT05962021 2023-08-01

Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation

Phase 2 Not yet recruiting

Non Squamous Non Small Cell Lung Cancer

NCT05891080 2023-06-06

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung